Compare CTSH & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSH | NTRA |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 32.9B |
| IPO Year | 1998 | 2015 |
| Metric | CTSH | NTRA |
|---|---|---|
| Price | $82.06 | $230.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 15 |
| Target Price | $88.87 | ★ $249.53 |
| AVG Volume (30 Days) | ★ 4.5M | 1.1M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.32 | N/A |
| Revenue | ★ $20,857,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | $8.99 | $33.77 |
| Revenue Next Year | $4.66 | $16.92 |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | 7.44 | ★ 38.17 |
| 52 Week Low | $65.15 | $125.38 |
| 52 Week High | $90.82 | $256.36 |
| Indicator | CTSH | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 44.72 |
| Support Level | $84.14 | $229.14 |
| Resistance Level | $85.93 | $250.00 |
| Average True Range (ATR) | 1.83 | 8.27 |
| MACD | -0.50 | -1.38 |
| Stochastic Oscillator | 8.48 | 21.29 |
Cognizant Technology Solutions is a multinational IT services provider that offers a range of consulting and business process outsourcing services. Originally founded in India, the company is headquartered in the US and serves enterprise customers spanning the financial services, healthcare, and resources industries. With most of its workforce located in India, Cognizant leverages a global delivery model that helps clients outsource their IT needs to offshore labor.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.